CYRX
Get informed when a big investor buys or sells
+ FollowOvervalued by 124.4% based on the discounted cash flow analysis.
| Market cap | $790.81 Million |
|---|---|
| Enterprise Value | $750.70 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.4 |
| Beta | 1.75 |
| Outstanding Shares | 49,897,817 |
| P/E Ratio | 10.15 |
|---|---|
| PEG | -31.18 |
| Price to Sales | 5.5 |
| Price to Book Ratio | 1.83 |
| Enterprise Value to Revenue | 4.1 |
| Enterprise Value to EBIT | -18.41 |
| Enterprise Value to Net Income | 9 |
| Total Debt to Enterprise | 0.31 |
| Debt to Equity | 0.47 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1449▲ 1.15% |
|---|---|
| Total Calls | 1,789,300▲ 36.30% |
| Total Puts | 259,200▲ 48.03% |
Holdings and activity of institutional investors.
| Ownership % | 91.38%▲ 1.75% |
|---|---|
| Total Invested | $378.86M▼ 12.16% |
| Investors Holding | 172▼ 6.00% |
No data
Controls taxation, trade, and entitlement spending (e.g., Medicare/Medicaid). Tax policy directly impacts corporate profitability, and Medicare/Medicaid coverage and pricing policies are major drivers of demand for medical instruments.
Allocates discretionary federal spending. Its subcommittees determine precise funding for healthcare programs, medical research, and government purchases, directly affecting demand and revenue streams for medical device companies.
Directly regulates the FDA (medical device approval and oversight), NIH (research funding), and labor laws, all of which are central to CryoPort's operations, product development, and manufacturing costs.
Oversees antitrust laws and intellectual property. Patent protection is critical for medical device manufacturers, and antitrust enforcement can impact M&A activity in the sector.
Oversees the Department of Veterans Affairs. Funding decisions directly impact government healthcare contractors, making it a crucial committee if CryoPort supplies medical devices to VA hospitals.